| 127 | 18 | 106 |
| 下载次数 | 被引频次 | 阅读次数 |
为了研究吉非替尼对中、晚期非小细胞肺癌(NSCLC)患者血清基质金属蛋白酶-7(MMP-7)、血清基质金属蛋白酶-9(MMP-9)表达的影响。本研究选取2014年9月至2015年8月本院收治的60例中、晚期NSCLC患者,根据随机数表法分为对照组30例和实验组30例。所有患者均采取营养、镇痛等对症支持治疗,对照组在此基础上采用GP方案,在第13天静脉滴注25 mg/m2的顺铂,在第1天、第8天静脉滴注1 000 mg/m2的吉西他滨;实验组在对症支持治疗基础上予以吉非替尼,口服,250 mg/次,1次/d,所有患者均以4周为1个治疗周期。观察患者治疗前和治疗1个周期后MMP-7、MMP-9表达情况,两组患者的不良反应率与临床疗效之间比较。通过治疗分析后,实验组的临床疗效率显著高于对照组,93.33%(28/30)比70.00%(21/30)(p<0.05)。实验组的血清MMP-7、MMP-9表达显著低于对照组,(0.27±0.07)ng/m L比(0.64±0.04)ng/m L,(270.92±30.24)ng/m L比(335.88±31.01)ng/m L(p<0.05)。实验组的不良反应率显著低于对照组,6.67%(2/30)比30.00%(9/30)(p<0.05)。研究结果表明在治疗中、晚期NSCLC患者中,吉非替尼能明显降低MMP-7、MMP-9的表达,临床疗效显著,安全性高。
Abstract：To study the effect of gefitinib on the expression of serum matrix metalloproteinases-7(MMP-7),matrix metalloproteinases-9(MMP-9) from patients with medium and advanced non-small cell lung cancer(NSCLC),we selected 60 cases of patients with medium and advanced NSCLC in our hospital from September 2014 to August 2015. We divided them into control group 30 cases and treatment group 30 cases according to the random number table method. We used symptomatic supportive treatment such as nutrition,analgesia to treat all patients.On this basis,we chose GP project for the control group,which was intravenous infusion 25 mg/m2 of cisplatin in13 days,intravenous infusion 1 000 mg/m2 of gemcitabine at first day and eighth day. On the basis of symptomatic supportive treatment,we used gefitinib in treatment group,which was taken orally,250 mg/time,once a day.All the patients were treated with 4 weeks as 1 cycle of treatment. We observed the expression of MMP-7,MMP-9 before and after 1 cycle of treatment,and compared the adverse reaction rate and the clinical effect of the two groups. After treatment analysis,the clinical efficacy rate of the treatment group rate was significantly higher than that of the control group,which was 93.33%(28/30) versus 70.00%(21/30)(p <0.05). The expression of serum MMP-7,MMP-9 of the treatment group was significantly lower than that of the control group,which were(0.27±0.07) ng/m L versus(0.64±0.04) ng/m L,(270.92±30.24) ng/m L versus(335.88±31.01) ng/m L(p<0.05). The adverse reaction rate of the treatment group was significantly lower than that of the control group,which was6.67%(2/30) versus 30.00%(9/30)(p <0.05). The results showed that in the treatment of medium and advanced NSCLC patients,gefitinib would obviously decrease the expression of MMP-7,MMP-9,and had significant clinical curative effect distinct and high safety.
Dai H.Y.,Xu L.,Xia C.W.,and Chen W.P.,2013,A randomized clinical study of geiftinib and pemetrexed as second lin therapy for advanced non-squamous non-small cell lung ca ncer,Zhongguo Feiai Zazhi(Chinese Journal of Lung Can cer),16(8):405-410(戴宏宇,徐玲,夏春伟,陈文萍,2013吉非替尼对比培美曲塞二线治疗晚期非鳞型非小细胞肺癌的随机对照临床研究,中国肺癌杂志,16(8):405-410)
Hu X.S.,Jiao S.C.,Zhang S.C.,Wang Z.H.,Wang M.Z.,Huan C.,Zheng R.S.,Li K.,Wang J.,Wang Y.J.,Ouyang X.NLv W.G.,Cheng G.,Hu H.C.,Luo R.C.,and Sun Y.,2012Efficacy and toxicity of pemetrexed or gemcitabine com bined with cisplatin in the treatment of patients with ad va nced non-small cell lung cancer,Zhongguo Feiai Zazh(Chinese Journal of Lung Cancer),15(10):569-575(胡兴胜,焦顺昌,张树才,王哲海,王孟昭,黄诚,郑荣生,李凯王洁,王雅杰,欧阳学农,吕文光,程刚,胡春宏,罗荣城孙燕,2012,培美曲塞及吉西他滨分别联合顺铂治疗初治晚期非小细胞肺癌安全性和有效性的随机对照研究,中国肺癌杂志,15(10):569-575)
Li Q.Q.,and Li E.Z.,2012,Curative effect of gefitinib on non-small-cell lung cancer and associated factors analysis Zhongguo Linchuang Yaolixue Zazhi(The Chinese Journa of Clinical Pharmacology),28(6):403-405(李倩琴,李恩泽,2012,吉非替尼作为一线治疗非小细胞肺癌疗效及相关影响因素,中国临床药理学杂志,28(6):403-405)
Li Y.,and Guo Q.S.,2014,Recearch progress of maintenanc therapy in andvanced non-small cell lung cancer,Zhonghu Zhongliu Fangzhi Zazhi(Chinese Journal of Cancer Preven tion and Treatment),21(10):800-804(李艳,郭其森,2014晚期非小细胞肺癌维持治疗进展,中华肿瘤防治杂志,21(10):800-804)
Liu H.,Hou W.,Wang H.,and Lin H.S.,2012,Clinical research on shenyi capsule combined with gefitinib for advanced non-small cell lung cancer:a report of 50 cases,Zhongy Zazhi(Journal of Traditional Chinese Medicine),53(11)933-935(刘浩,侯炜,王辉,林洪生,2012,参一胶囊联合吉非替尼治疗晚期非小细胞肺癌50例临床研究,中医杂志,53(11):933-935)
Ma W.,Gilligan B.M.,Yuan J.,and Li T.,2016,Current statu and perspectives in translational biomarker research fo PD-1/PD-L1 immune checkpoint blockade therapy,Journa of Hematology&Oncology,9(1):47
Ma Y.X.,Huang Y.,Zhao H.Y.,Liu J.L.,Chen L.K.,Wu H.Y.and Zhou N.N.,2013,The cost-effectiveness analysis o gefitinib or erlotinib in the treatment of advanced EGFR mu tant non-small cell lung cancer patients,Zhongguo Feiai Za zhi(Chinese Journal of Lung Cancer),16(4):203-210(马宇翔,黄岩,赵洪云,刘俊玲,陈丽昆,吴海鹰,周宁宁,2013晚期EGFR突变型非小细胞肺癌患者接受吉非替尼或厄洛替尼治疗的成本效益分析,中国肺癌杂志,16(4)203-210)
Mir R.,Masroor M.,Javid J.,Ahamad I.,Farooq S.,Yadav P.Zuberi M.,Lone M.,Ray P.C.,and Saxena A.,2016,Clini cal implications of cytosine deletion of exon 5 of P53 gen in non small cell lung cancer patients,South Asian Journa of Cancer,5(1):33-36
Predina J.D.,Keating J.,Venegas O.,Nims S.,and Singha S.,2016,Neoadjuvant intratumoral immuno-gene therap for non-small cell lung cancer,Discov.Medicine,21(116)275-281
Schaal C.,and Chellappan S.,2016,Nicotine-mediate d regula tion of nicotinic acetylcholine receptors in non-small cel lung adenocarcinoma by E2F1 and STAT1 transcription fac tors,PLo S One,11(5):e0156451
Seiichiro S.,Masato K.,Naoki I.,Shigeki K.,Tomoyuki F.Noriyuki E.,Yutaro N.,Koshi Y.,Mikio T.,Shiro I.Kazuhiro A.,Masafumi M.,Takashi Y.,Hiroshi W.,Hirosh H.,and Takafumi S.,2016,Sequential addition of aprepitan in patients receiving carboplatin-based chemotherapy,Medi cal Oncology,33(7):65
Shinohara S.,Hanagiri T.,Taira A.,Takenaka M.,Oka S.Chikaishi Y.,Uramoto H.,So T.,Yamada S.,and Tanaka F.2016,Immunohistochemical expression and serum levels o CD44 as prognostic indicators in patients with non-smal cell lung cancer,Oncology,90(6):327-338
Song Y.,and Yang W.,2015,Medical treatment of advanced non-small cell lung cancer:progress in 2014,Jiefangjun Yixue Zazhi(Medical Journal of Chinese People's Libera tion Army),40(1):10-15(宋勇,杨雯,2015,2014年晚期非小细胞肺癌内科治疗进展,解放军医学杂志,40(1)10-15)
譒tulhofer B.D.,Martinac I.,Ledic D.D.,Ceovic R.,Bilic I.,and Marinovic B.,2016,Adverse reaction to cetuximab,an epi dermal growth factor receptor inhibitor,Acta Dermatoven erol Croat,24(1):70-72
Wang Q.,Wang M.C.,He X.R.,Gao T.M.,Cao H.,Dou W.J.and Tian J.H.,2012,Meta-analysis on treatment of non small cell lung cancer with brucea javanica oil emulsion in combination with platinum-contained first-line chemothera py,Zhongguo Zhongyao Zazhi(China Journal of Chinese Materia Medica),37(13):2022-2029(王权,王满才,何曦冉高天明,曹慧,窦文婕,田金徽,2012,鸦胆子油乳联合含铂类一线化疗方案治疗非小细胞肺癌的Meta分析,中国中药杂志,37(13):2022-2029)
Wang R.,Shi D.Q.,Xie H.,Li W.B.,Tian W.,and Jia Z.P.,2013Research progress on EGFR gene mutation in non-small cel lung cancer,Zhongguo Yaolixue Tongbao(Chinese Pharm acological Bulletin),29(1):22-26(王荣,石冬琴,谢华,李文斌,田薇,贾正平,2013,非小细胞肺癌中EGFR基因突变及靶向药物治疗研究进展,中国药理学通报,29(1):22-26)
Wu S.W.,Cheng Z.N.,Yu L.,Song W.Q.,and Tao Y.S.,2012Expressions of E-cad and MMP-2 in non-small cell lung cancer and their relationship to vasculogenic mimicry Zhongguo Laonianxue Zazhi(Chinese Journal of Gerontolo gy),32(17):3623-3626(武世伍,承泽农,俞岚,宋文庆,陶仪声,2012,钙黏蛋白和基质金属蛋白酶-2在非小细胞肺癌中的表达及其与血管生成拟态的关系,中国老年学杂志,32(17):3623-3626)
Xuan X.L.,An C.S.,and Zhou C.C.,2013,The mechanism o gefitinib resistance induced by hepatocyte growth factor in sensitive non-small cell lung cancer cells in vitro,Zhongguo Feiai Zazhi(Chinese Journal of Lung Cancer),16(1):1-6(玄香兰,安昌善,周彩存,2013,肝细胞生长因子诱导敏感非小细胞肺癌细胞对吉非替尼耐药及机制的研究,中国肺癌杂志,16(1):1-6)
Yang X.N.,and Wu Y.L.,2004,RECIST-New guidelines to eval uate the response to treatment in solid tumors,Xunzheng Yixue(The Journal of Evidence-Based Medicine),4(2)85-90(杨学宁,吴一龙,2004,实体瘤治疗疗效评价标准-RECIST,循证医学,4(2):85-90)
Zhang L.C.,Adili·S.L.,Zhang G.Q.,Han F.,Fang X.Z.,an Zhang Y.H.,2012,Expression and clinical significance o IL-17 and MMP-9 in NSCLC patients of han and uighur Zhongliu Fangzhi Yanjiu(Cancer Research on Prevention and Treatment),39(7):798-801(张鲁昌,阿迪力·萨来,张国庆,韩峰,房新志,张银华,2012,IL-17,MMP-9在汉族和维吾尔族非小细胞肺癌患者中的表达及临床意义,肿瘤防治研究,39(7):798-801)
基本信息:
DOI：10.13417/j.gab.035.002909
中图分类号:R734.2
引用信息:
[1]方利洲,刘凌,张剑青,等.吉非替尼对中、晚期非小细胞肺癌患者血清MMP-7、MMP-9表达的影响[J].基因组学与应用生物学,2016,35(11):2909-2915.DOI:10.13417/j.gab.035.002909.
基金信息:
云南省卫生科技计划项目(2016NS045)资助
2016-11-25
2016-11-25